Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.83 |
---|---|
High | 18.83 |
Low | 18.83 |
Bid | 18.80 |
Offer | 18.85 |
Previous close | 18.77 |
Average volume | 199.90 |
---|---|
Shares outstanding | 118.69m |
Free float | 111.55m |
P/E (TTM) | 38.97 |
Market cap | 2.47bn USD |
EPS (TTM) | 0.5335 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 07:06 BST.
More ▼
Announcements
- Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
- Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
- Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
- Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
- Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
- Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
- Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
- Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
- Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
- Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
More ▼